Two Sides of Nanovaccines and Nanomedicines in Cancer Treatments

Tuan Anh Nguyen is a Senior Principal Research Scientist at the Institute for Tropical Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam. He received a BS in physics from Hanoi University in 1992, a BS in economics from Hanoi National Economics University in 1997, and a PhD in chemistry from the Paris Diderot University, France, in 2003. He was a Visiting Scientist at Seoul National University, South Korea, in 2004, and the University of Wollongong, Australia, in 2005. He then worked as a Postdoctoral Research Associate and Research Scientist at Montana State University, United States in 2006-09. In 2012 he was appointed as the Head of the Microanalysis Department at the Institute for Tropical Technology. His research areas of interest include smart sensors, smart networks, smart hospitals, smart cities, complexiverse, and digital twins. He has edited more than 74 books for Elsevier, 12 books for CRC Press, 1 book for Springer, 1 book for RSC, and 2 books for IGI Global. He is the Editor-in-Chief of Kenkyu Journal of Nanotechnology & Nanoscience. Dr. Bhupendra Gopalbhai Prajapati is Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India, and serves as Adjunct Professor in the Department of Industrial Pharmacy at Silpakorn University, Thailand. His academic, research, and industry expertise focuses on lipid‑based formulations, nano‑ and microparticulate drug delivery systems, and strategies to enhance drug bioavailability. Dr. Prajapati has received several academic and professional honors recognizing excellence in teaching and research. He has made substantial scholarly contributions through research and review publications, book chapters, and edited volumes in pharmaceutical sciences. Actively engaged in postgraduate and doctoral mentoring, he supports research training in advanced drug delivery and formulation science. Dr. Prajapati also serves in editorial and section‑editor roles for international scientific publications, contributing to the advancement and quality of pharmaceutical research dissemination. Dr. Devesh U. Kapoor is Professor of Pharmaceutics at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, affiliated with Gujarat Technological University. His academic and research expertise centers on pharmaceutics, nanodrug delivery, and modified‑release drug delivery systems. Dr. Kapoor has made extensive scholarly contributions through research and review publications, book chapters, and edited volumes with international publishers. He is actively involved in postgraduate and doctoral research supervision in advanced drug delivery technologies. His editorial experience includes serving in senior editorial roles for international journals across pharmacology, pharmaceutics, and biomedical sciences, along with regular peer‑review activity for a wide range of scientific journals. Dr. Kapoor has also secured competitive research and academic development funding and is a frequent invited speaker at national scientific meetings, workshops, and academic programs.

• Part 1: Fundamentals1. Introduction to nanovaccine in cancer treatments2. Introduction to nanomedicine in cancer treatments3. Sensors for Cancer Detection4. Current Perspectives of Nanomedicines (in Cancer Treatment)5. Current Perspectives of Nanovaccines and Nanomedicines (in Cancer Treatment)Part 2: Advantage and Application of Nanovaccine and Nanomedicine6. Advantage of cancer Nanomedicine7. Advantage of Targeted Nanomedicine (in Cancer Treatment)8. Advantage of nanovaccine (in cancer treatment)9. Nanovaccines and Nanomedicines in cancer treatment: Current LandscapePart 3: The Other Side of Nanovaccine and Nanomedicine10. Side Effect and Toxicity of Nanovaccine (in Cancer Treatment)11. Side effect and toxicity of nanomedicine (in cancer treatment)12. Crossing the Barrier, Crossing the Line: Neurotoxicity of Nanomedicines in Brain Cancer Therapy 13. Side effects and toxicity of nanoparticles in cancer treatment14. Toxicity of Metal Oxide Nanoparticles in Nanomedicine. Mechanisms and Implications15. Nanotoxicity, safety assessment, regulatory aspect and clinical trial of nanovaccines/nanomedicine16. Nanotoxicity/nano-genotoxicity in cancer care17. Toxicity evaluation and management for nanoparticles used in the cancer therapy18. Nanoparticle Toxicity in Cancer NanomedicinePart 4: Challenge and Perspectives19. Nano-medicines and Nano-vaccines Manufacturing20. Ethics in Nanomedicine and Nanovaccine in Cancer Treatment21. Ethics in Cancer Nanomedicine22. Ethics and regulations in nanomedicine/nanovaccines23. Regulating nanomedicine: challenges and opportunities24. Safety Assessment for Nanomedicines and Nanovaccines25. Manufacturing of nanomedicine/nanovaccine on Large Scale: Challenges and Issues26. Future perspectives of nanovaccines and nanomedicines